National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of Ozurdex® in the treatment of macular oedema following Retinal Vein Occlusion.

Rapid Review

Commenced Completed Outcome
12/11/2010 16/12/2010 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 24/11/2011  16/03/2012  Reimbursement Not Recommended

We believe that at the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion.

Ozurdex® Summary

July 2013

Following resubmission of pricing information the NCPE conclude that Ozurdex® is a cost effective treatment strategy versus observation (base case) in RVO. The ICER for Ozurdex® versus observation is €25,601/QALY (basecase).   The probability of cost effectiveness at a threshold of €45,000/QALY is 88.97%.